The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome disease.
Globally our industry is researching and developing more than 7,000 new medicines.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK.
Download the full report here.
Citation; Sampson, C., O’Neill, P. & Lorgelly, P. (2018). The Impact of New Medicines in the NHS: 70 Years of Innovation . OHE Consulting Report, London: Office of Health Economics.
Interviewees came from scientific, clinical, practicing, academic, and regulatory backgrounds in the context of new medicines in the UK and are, or were previously, employed by the NHS, the Medicines and Healthcare products Regulatory Agency (MHRA), NICE, universities or non-academic research institutions.
Several interviewees had been employed in industry at some point in their career. Medical fields and specialties of expertise in the group included cardiology, gastroenterology, general practice, infectious disease, paediatrics, psychiatry, respiratory medicine, and surgery.